Navigation Links
Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Date:8/7/2008

SAN RAMON, Calif., Aug. 7 /PRNewswire/ -- Odyssey Thera, Inc. announced that it has received a milestone payment from Pfizer Inc, following Pfizer's decision to progress a discovery stage drug candidate into pre-clinical development. The drug candidate was extensively studied by Odyssey Thera as part of the ongoing collaboration with Pfizer.

"We are very pleased with the progress of the collaboration with Pfizer," said John K. Westwick, Ph.D., Odyssey Thera's President and CEO. "Progress on this and other discovery programs with Pfizer demonstrates the power of our unique cellular analysis platform to improve knowledge of drug mechanisms and selectivity."

In August 2006, Odyssey Thera announced its third alliance with Pfizer. Under the terms of the multi-year agreement, Odyssey Thera is collaborating on multiple Pfizer drug discovery projects, and has received upfront payments, research and capital expenditure funding, and previous success-based milestones. The achievement of this milestone announced today is the Company's first such milestone to be earned for contributing to the advancement of a drug candidate.

About Odyssey Thera, Inc.

Odyssey Thera's patented technology measures disease-relevant pathway activity within living human cells. Rapid identification of on-target and off-pathway activities of lead compounds enables selection of drug candidates with favorable safety and selectivity profiles. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical company partners.

To learn more about Odyssey Thera, please visit http://www.odysseythera.com


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
2. Odyssey Thera Granted U.S. Patent for Animal Imaging
3. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
4. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. CV Therapeutics Reports 2008 Second Quarter Financial Results
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
10. United Therapeutics Reports Second Quarter 2008 Financial Results
11. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PARK, N.C. , Sept. 17, 2014  The ... presentation topics that will be featured at the conference, ... Conference Center on December 3 and 4, 2014. Researchers, ... are invited to hear the following: ... UC San Diego Skaggs School of Pharmacy ...
(Date:9/17/2014)... COLUMBIA, Md. (PRWEB) September 17, 2014 ... Nexera-e Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which ... most complex sample matrices. The system provides ... of sample analytes, which is beneficial to ... food extracts, and natural products. , Comprehensive ...
(Date:9/17/2014)... San Jose, California (PRWEB) September 17, 2014 ... disintegrated by naturally occurring microorganisms such as bacteria, ... subsequently transformed into water, methane, biomass, inorganic compounds, ... With enhanced processability, expanding customer base and improved ... environmentally beneficial and economically viable alternative to conventional ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., ... eClinical Solutions, today announced three of its experts are ... for Clinical Data Management to be held September 28 ... . The Company also announced the innovative ... overall quality in clinical trials acquired earlier this year, ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... ON ALS CLINICALS AND DRUG DEVELOPMENT, ROCKVILLE, ... (Amex: CUR ) announced that Dr. Thomas ... President, Research. He will be,working with Dr. Karl ... the company,s upcoming clinical trial for ALS,(Amytrophic Lateral ...
... Symbol: MS, EDMONTON, July 30 /PRNewswire-FirstCall/ - BioMS ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... "Focus on Healthcare Conference" in New York., ... WHERE: The Millennium Broadway Hotel, New York ...
... receives custom orders from leading semiconductor manufacturers, officially putting revenue ... ... Seattle, WA (PRWEB) July 30, 2008 -- Carbon Nanoprobes, Inc ... welcomes its first revenue from two major semiconductor manufacturers. Contracts ...
Cached Biology Technology:Neuralstem Fills Key Product Development Position 2BioMS Medical to present at BMO Healthcare Conference 2Startup Nanotech Firm Books First Revenue From Large Chip Makers 2Startup Nanotech Firm Books First Revenue From Large Chip Makers 3
(Date:9/17/2014)... decades of decline, grasses have returned to some once-denuded ... marsh in those places seems healthy again, but a ... the marsh coastal protection remains diminished. , ... hasn,t come back," said ecologist Mark Bertness, professor of ... in the journal Biological Conservation . "The metric ...
(Date:9/17/2014)... a new crime unit designed to fight food fraud ... horse meat being passed off as beef scientists ... adulteration. They describe their approach, which represents a vast ... Agricultural and Food Chemistry . , Hans-Ulrich Humpf and ... economic problem. But they also say that adding, for ...
(Date:9/17/2014)... bacterial infections, including MRSA and MSSA could be ... that mimic the scaly surface of shark skin, ... journal Antimicrobial Resistance and Infection Control . ... prevented the spread of human disease bacteria through ... is an arrangement of ridges formulated to resemble ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Sharks' skin has teeth in the fight against hospital superbugs 2
... Researchers at Indiana University School of Medicine are several steps closer ... cells could be used to let him or her hear the ... able to transform, in the laboratory, stem cells taken from adult ... nerve cells -- neurons -- found in the ear. The results ...
... at New York University and Rockefeller University have ... shown to have key roles in gene regulation, ... mammals. MicroRNAs are a recently discovered large class ... complementary sites in target messenger RNA to regulate ...
... to visualize more of the arteries in the lungs, ... seeing more may have little impact on the patient's ... 198 patients with suspected pulmonary embolism. About half of ... 100 patients had a single-detector CT examination. The radiology ...
Cached Biology News:Researchers Closer To Helping Hearing-Impaired Using Stem Cells 2NYU, Rockefeller researchers find complexity of regulation by microRNA genes 2Newer imaging techniques may lead to over-treatment 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Request Info...
... 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... to 1 mg/ml,(0.26 M to 2.6 mM) Sensitivity: around 0.2 ug/ml ...
See product name for description....
Biology Products: